Log in to save to my catalogue

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Phase 2 study of pembrolizumab in patients with advanced rare cancers

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_633cee93179a43e799cae34404daa006

Publication information

Publisher

England: BMJ Publishing Group Ltd

More information

Scope and Contents

Contents

BackgroundPatients with advanced rare cancers have poor prognosis and few treatment options. As immunotherapy is effective across multiple cancer types, we aimed to assess pembrolizumab (programmed cell death 1 (PD-1) inhibitor) in patients with advanced rare cancers.MethodsIn this open-label, phase 2 trial, patients with advanced rare cancers whos...

Alternative Titles

Full title

Phase 2 study of pembrolizumab in patients with advanced rare cancers

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_633cee93179a43e799cae34404daa006

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_633cee93179a43e799cae34404daa006

Other Identifiers

ISSN

2051-1426

E-ISSN

2051-1426

DOI

10.1136/jitc-2019-000347

How to access this item